Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 22;108(11):3011–3024. doi: 10.3324/haematol.2022.282474

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2023 Ferrata Storti Foundation

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Figure 6. — IL-27 level is reduced in the blood of leukemic mice and chronic lymphocytic leukemia patients and IL-27 neutralization enhanced chronic lymphocytic leukemia development as observed in Ebi3^-/- mice. (A) (Left) Serum levels of interleukin 27 (IL-27) in mice before and after chronic lymphocytic leukemia (CLL) development. (Right) Correlation between IL-27 serum levels and CLL development in mice measured by enzyme-linked immosorbant assay (ELISA). (B) Serum levels of IL-27 in CLL patients (N=53) and healthy controls (N=16) measured by ELISA. (C-F) (Right) A cohort of recipient Ctrl mice was intraperitoneally (i.p.) injected with α-IL-27 or isotype control antibodies and subsequently adoptively transferred with splenocytes from leukemic Eμ-TCL1 mice. Mice were bled weekly to evaluate peripheral disease development. The injection of antibodies was maintained once per week until euthanasia. (C) (Left) Percentages of circulating leukemic CD5⁺ CD19⁺ cells in the 2 groups (N=7 for isotype group and N=8 for α-IL-27 group, two-way ANOVA test. (D-F) Mice were euthanized and their splenocytes were analyzed by flow cytometry. (D) Number of CLL cells in the spleen of both experimental conditions. (E) Distribution of cells in cluster C1 among CD8⁺ T cells from isotype- and α-IL-27-treated mice. (F) Percentage of KLRG1⁺ or Ki67⁺ Treg from isotype- and α-IL-27-treated mice. Unpaired t test, *P<0.05, **P<0.01, ****P<0.0001.